KO

KOREAN DRUG CO., LTD.

Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.

014570 | KO

Overview

Corporate Details

ISIN(s):
KR7014570006
LEI:
Country:
South Korea
Address:
경기도 이천시 신둔면 원적로 69-10, 이천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Korean Drug Co., Ltd. is an established pharmaceutical company with over 50 years of experience in developing, manufacturing, and marketing therapeutic drugs. The company's portfolio includes both prescription (ETC) medicines for various conditions and over-the-counter (OTC) products, such as its 'Geunalen' brand of painkillers. Leveraging state-of-the-art production facilities and proprietary technology, the company produces a range of finished pharmaceutical products, and its offerings may also extend to health supplements and medical supplies. The company is committed to developing high-quality medicines for public health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-13 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.2 KB
2025-08-11 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.5 KB
2025-07-02 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-06-30 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.6 KB
2025-06-05 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-06-02 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1019.2 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.7 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.6 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 18.4 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 444.5 KB
2025-03-06 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-03-04 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.5 KB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 102.6 KB

Automate Your Workflow. Get a real-time feed of all KOREAN DRUG CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOREAN DRUG CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOREAN DRUG CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.